Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GR2301
- Development stage
- Phase 2
- Lead developer
- Zhixiang Jintai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
**GR2301** is a recombinant fully human monoclonal antibody that specifically binds to human interleukin-15 (IL-15), inhibiting its activity to modulate immune responses dysregulated in autoimmune conditions. Initially developed by Chongqing Genrix Biopharmaceutical Co., Ltd., it targets diseases involving IL-15 overexpression, such as vitiligo, with potential broader applications in autoimmune disorders. Its investigational new drug application for clinical trials has been approved in China, and it is advancing in early-stage development for dermatological indications within skin and musculoskeletal disease areas.[1][3][5]
02
Targets
IL15 (Interleukin 15)
Beyond the preview
Go deeper on GR2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GR2301.